title: Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin's lymphoma.
  
  
  METHODS
  A total of 127 patients with confirmed non-Hodgkin's lymphoma who underwent FDG PET within 60 days from the last administration of G-CSF were retrospectively reviewed. Thirty age-matched and sex-matched healthy controls were also included to evaluate physiological FDG uptake. PET/CT examinations were retrospectively reviewed, and maximum standardized uptake value (SUVmax) was measured by placing volumetric regions of interest over each thoracic and lumbar vertebra on PET images referring to CT images. Bone marrow SUV was defined as the mean SUVmax of the vertebra. The correlation between the interval after G-CSF and the bone marrow SUV was plotted and analyzed with polynomial approximation.
  
  
  RESULTS
  In controls, physiological bone marrow SUV of the spine was determined. In patients with lymphoma, bone marrow SUV decreased over time and reached a plateau at about 14 days after G-CSF administration, and this was higher by 5% than the plateau at 10 days. SUV declined to the 'physiological range', that is, mean+1 standard deviation of patients, at about 7 days.
  
  
  CONCLUSIONS
  For a PET/CT study, an interval of 10 days after G-CSF administration is recommended to minimize the influence of G-CSF on the bone marrow when evaluating treatment response in patients with non-Hodgkin's lymphoma.
authors.affiliation: Department of Radiology, Kinki University Hospital, Osaka-Sayama, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Hanaoka
authors.forename: Makoto
authors.initials: M
authors.lastname: Hosono
authors.forename: Kimio
authors.initials: K
authors.lastname: Usami
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Tatsumi
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Yamazoe
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Komeya
authors.forename: Norio
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: Kazunari
authors.initials: K
authors.lastname: Ishii
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Sumita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001692:Biological Transport / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects* / Q000378:metabolism*; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D013131:Spine / Q000276:immunology; D013997:Time Factors; D055815:Young Adult
chemical_list: D019788:Fluorodeoxyglucose F18; D016179:Granulocyte Colony-Stimulating Factor